1. Opportunities and challenges: interleukin-22 comprehensively regulates polycystic ovary syndrome from metabolic and immune aspects
- Author
-
Yuli Geng, Zhuo Liu, Runan Hu, Wenwen Ma, Xiao Wu, Haoxu Dong, Kunkun Song, Xiaohu Xu, Yanjing Huang, Fan Li, Yufan Song, and Mingmin Zhang
- Subjects
PCOS ,IL-22 ,Metabolism ,Treatment ,Mechanism ,Gynecology and obstetrics ,RG1-991 - Abstract
Abstract Polycystic ovary syndrome (PCOS) is known as a prevalent but complicated gynecologic disease throughout the reproductive period. Typically, it is characterized by phenotypic manifestations of hyperandrogenism, polycystic ovary morphology, and persistent anovulation. For now, the therapeutic modality of PCOS is still a formidable challenge. Metabolic aberrations and immune challenge of chronic low-grade inflammatory state are significant in PCOS individuals. Recently, interleukin-22 (IL-22) has been shown to be therapeutically effective in immunological dysfunction and metabolic diseases, which suggests a role in the treatment of PCOS. In this review, we outline the potential mechanisms and limitations of IL-22 therapy in PCOS-related metabolic disorders including its regulation of insulin resistance, gut barrier, systemic inflammation, and hepatic steatosis to generate insights into developing novel strategies in clinical practice.
- Published
- 2023
- Full Text
- View/download PDF